A new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study

BackgroundMagnetic resonance imaging (MRI) plays an important role in tumor detection/diagnosis. The use of exogenous contrast agents (CAs) helps to improve the discrimination between lesion and neighbouring tissue, but most of the currently available CAs are non-specific. Assessing the performance of new, selective CAs requires exhaustive assays and large amounts of material. Accordingly, in a preliminary screening of new CAs, it is important to choose candidate compounds with good potential for in vivo efficiency. This screening method should reproduce as close as possible the in vivo environment. In this sense, a fast and reliable method to select the best candidate CAs for in vivo studies would minimize time and investment cost, and would benefit the development of better CAs.ResultsThe post-mortem ex vivo relative contrast enhancement (RCE) was evaluated as a method to screen different types of CAs, including paramagnetic and superparamagnetic agents. In detail, sugar/gadolinium-loaded gold nanoparticles (Gd-GNPs) and iron nanoparticles (SPIONs) were tested. Our results indicate that the post-mortem ex vivo RCE of evaluated CAs, did not correlate well with their respective in vitro relaxivities. The results obtained with different Gd-GNPs suggest that the linker length of the sugar conjugate could modulate the interactions with cellular receptors and therefore the relaxivity value. A paramagnetic CA (GNP (E_2)), which performed best among a series of Gd-GNPs, was evaluated both ex vivo and in vivo. The ex vivo RCE was slightly worst than gadoterate meglumine (201.9 ± 9.3% versus 237 ± 14%, respectively), while the in vivo RCE, measured at the time-to-maximum enhancement for both compounds, pointed to GNP E_2 being a better CA in vivo than gadoterate meglumine. This is suggested to be related to the nanoparticule characteristics of the evaluated GNP.ConclusionWe have developed a simple, cost-effective relatively high-throughput method for selecting CAs for in vivo experiments. This method requires approximately 800 times less quantity of material than the amount used for in vivo administrations.

[1]  Elodie Boisselier,et al.  Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. , 2009, Chemical Society reviews.

[2]  Peter Caravan,et al.  Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. , 2006, Chemical Society reviews.

[3]  Sophie Laurent,et al.  Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. , 2006, Contrast media & molecular imaging.

[4]  P. Perriat,et al.  Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. , 2007, Journal of the American Chemical Society.

[5]  G. Moro,et al.  Conformational behaviour determines the low-relaxivity state of a conditional MRI contrast agent. , 2009, Physical chemistry chemical physics : PCCP.

[6]  Val M. Runge,et al.  Brain Tumor Enhancement in Magnetic Resonance Imaging at 3 Tesla: Intraindividual Comparison of Two High Relaxivity Macromolecular Contrast Media With a Standard Extracellular Gd-Chelate in a Rat Brain Tumor Model , 2009, Investigative radiology.

[7]  W. Cai,et al.  Facile synthesis of superparamagnetic magnetite nanoparticles in liquid polyols. , 2007, Journal of colloid and interface science.

[8]  S. Swanson,et al.  Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement , 2008, International journal of nanomedicine.

[9]  A. Luciani,et al.  Glucose-receptor MR imaging of tumors: study in mice with PEGylated paramagnetic niosomes. , 2004, Radiology.

[10]  J. Rojo,et al.  Gold Glyconanoparticles as Water-Soluble Polyvalent Models To Study Carbohydrate Interactions. , 2001, Angewandte Chemie.

[11]  Peter Caravan,et al.  Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. , 2009, Contrast media & molecular imaging.

[12]  C. Kremser,et al.  Lectin–Gd-Loaded Chitosan Hydrogel Nanoparticles: A New Biospecific Contrast Agent for MRI , 2011, Molecular Imaging and Biology.

[13]  I. García,et al.  Glyconanoparticles as multifunctional and multimodal carbohydrate systems. , 2013, Chemical Society reviews.

[14]  I. García,et al.  Glyconanoparticles: multifunctional nanomaterials for biomedical applications. , 2010, Nanomedicine.

[15]  Sophie Laurent,et al.  Contrast agents: magnetic resonance. , 2008, Handbook of experimental pharmacology.

[16]  Philippe Robert,et al.  Recent advances in iron oxide nanocrystal technology for medical imaging. , 2006, Advanced drug delivery reviews.

[17]  Peter Caravan,et al.  Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. , 2009, Accounts of chemical research.

[18]  Ralph Weissleder,et al.  Multifunctional magnetic nanoparticles for targeted imaging and therapy. , 2008, Advanced drug delivery reviews.

[19]  J. Santamaría,et al.  Surface functionalization for tailoring the aggregation and magnetic behaviour of silica-coated iron oxide nanostructures , 2012, Nanotechnology.

[20]  C. Robic,et al.  Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. , 2008, Chemical reviews.

[21]  Shelton D Caruthers,et al.  Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI , 2004, Magnetic resonance in medicine.

[22]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Nuria Genicio,et al.  Sugar/gadolinium-loaded gold nanoparticles for labelling and imaging cells by magnetic resonance imaging. , 2013, Biomaterials science.

[24]  J. M. de la Fuente,et al.  Glyconanoparticles: types, synthesis and applications in glycoscience, biomedicine and material science. , 2006, Biochimica et biophysica acta.

[25]  Joop A. Peters,et al.  RELAXATION BY METAL-CONTAINING NANOSYSTEMS , 2005 .

[26]  S. Foxley,et al.  New vanadium-based magnetic resonance imaging probes: clinical potential for early detection of cancer , 2009, JBIC Journal of Biological Inorganic Chemistry.

[27]  Chunxin Zhang,et al.  Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[28]  A. Bernad,et al.  Gold Glyconanoparticles as New Tools in Antiadhesive Therapy , 2004, Chembiochem : a European journal of chemical biology.

[29]  Vasilis Ntziachristos,et al.  Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging , 2010, Particle and Fibre Toxicology.

[30]  María J. Ledesma-Carbayo,et al.  DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data , 2013, BMC Bioinformatics.

[31]  T. Pellegrino,et al.  From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. , 2010, Pharmacological research.

[32]  C. Arús,et al.  An iron-based T1 contrast agent made of iron-phosphate complexes: In vitro and in vivo studies , 2007, Magnetic Resonance Materials in Physics, Biology and Medicine.

[33]  Xueding Wang,et al.  Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles , 2009, Proceedings of the National Academy of Sciences.

[34]  S. Cerdán,et al.  Paramagnetic Gd-based gold glyconanoparticles as probes for MRI: tuning relaxivities with sugars. , 2009, Chemical communications.

[35]  Jinho Park,et al.  Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy , 2012, Theranostics.

[36]  J L Evelhoch,et al.  Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.

[37]  D. Gillespie,et al.  Hypoxia‐regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme , 2008, Cancer.

[38]  N. Wang,et al.  Drug Elimination Kinetics Following Subconjunctival Injection Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2008, Pharmaceutical Research.

[39]  J. Creyghton,et al.  Determination of in vivo rat muscle Gd-DTPA relaxivity at 6.3 T , 1999, Magnetic Resonance Materials in Physics, Biology and Medicine.

[40]  W. J. Lorenz,et al.  Pharmacokinetic Mapping of the Breast: A New Method for Dynamic MR Mammography , 1995, Magnetic resonance in medicine.

[41]  U Himmelreich,et al.  Efficient stem cell labeling for MRI studies. , 2008, Contrast media & molecular imaging.

[42]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[43]  F. Cañada,et al.  Modulating glycosidase degradation and lectin recognition of gold glyconanoparticles. , 2009, Carbohydrate research.

[44]  C Arús,et al.  Perturbation of mouse glioma MRS pattern by induced acute hyperglycemia , 2008, NMR in biomedicine.

[45]  A. Roch,et al.  Magnetic resonance relaxation properties of superparamagnetic particles. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[46]  John M. Hancock,et al.  EuroPhenome and EMPReSS: online mouse phenotyping resource , 2008 .

[47]  E. Giralt,et al.  Shuttle-mediated drug delivery to the brain. , 2011, Angewandte Chemie.

[48]  Walter H Backes,et al.  Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. , 2005, Radiology.

[49]  M. de Felice,et al.  Age-Related Reference Intervals of the Main Biochemical and Hematological Parameters in C57BL/6J, 129SV/EV and C3H/HeJ Mouse Strains , 2008, PloS one.

[50]  J R Griffiths,et al.  Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging , 2003, British Journal of Cancer.

[51]  Vasilis Ntziachristos,et al.  High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. , 2002, Bioconjugate chemistry.

[52]  M. Marradi,et al.  Glyconanoparticles polyvalent tools to study carbohydrate-based interactions. , 2010, Advances in carbohydrate chemistry and biochemistry.

[53]  R. D. Bolskar.  Gadofullerene MRI contrast agents. , 2008, Nanomedicine.

[54]  W. Krause.  Contrast Agents II , 2002 .

[55]  U. Karst,et al.  Determination of gadolinium-based MRI contrast agents in biological and environmental samples: a review. , 2013, Analytica chimica acta.

[56]  M Hatanaka,et al.  Transport of sugars in tumor cell membranes. , 1974, Biochimica et biophysica acta.

[57]  P. Couvreur,et al.  High-relaxivity magnetic resonance imaging (MRI) contrast agent based on supramolecular assembly between a gadolinium chelate, a modified dextran, and poly-beta-cyclodextrin. , 2008, Chemistry.

[58]  J. Santamaría,et al.  Development of Stable, Water-Dispersible, and Biofunctionalizable Superparamagnetic Iron Oxide Nanoparticles , 2011 .

[59]  Ajay Kumar Gupta,et al.  Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.

[60]  Valery V Tuchin,et al.  Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery , 2009, Journal of biophotonics.

[61]  R. Drezek,et al.  Gold-silver alloy nanoshells: a new candidate for nanotherapeutics and diagnostics , 2011, Nanoscale research letters.

[62]  C. Arús,et al.  Ex vivo assessment of polyol coated-iron oxide nanoparticles for MRI diagnosis applications: toxicological and MRI contrast enhancement effects , 2014, Journal of Nanoparticle Research.